Cortical Visual Impairment Across a Range of Neurodevelopmental Disorders (NDD): Clinical Characterization, Diagnostic Tool Evaluation, and Association with Developmental Outcomes

Abstract

Cortical visual impairment (CVI) is particularly relevant in children with neurodevelopmental disorders (NDDs) yet remains underdiagnosed. This study assessed the prevalence and severity of CVI in four neurogenetic conditions: STXBP1, SLC6A1, Ring 14, and 8p-related disorders. We also evaluated the CCSA-Clinician vision subdomain (CCSA-vision) as a diagnostic tool and examined the association between CVI and developmental outcomes. A retrospective chart review of 85 patients found CVI in 44%, most commonly in 8p (54%) and STXBP1 (50%); no cases were seen in SLC6A1. The CCSA-vision subdomain effectively distinguished CVI cases

Author

Megan Abbott | MDa,c | Katie Angione | MS | CGCa,c | Megan Stringfellow | BSb | Kristina Malik | MDb,d | Margarita Saenz | MDb,e | Emily McCourt | MDb,f | Lori Silveira | PhDc | Andrea Miele | PhDb,c | Tim. A. Benke | MD | PhDb,c | Scott Demarest | MD | MSCSa,c

The Project 8p Foundation (Project 8p) was created in 2018 to:

  • Accelerate future treatments, not only for 8p, but potentially for other chromosome-wide diseases as well.
  • Lead with knowledge from patients. Currently, there is no cure for 8p disorders, nor is there a standard course of treatment.

The Project 8p Foundation (Project 8p) was created in 2018 to:

  • Raise transformative funding for pioneering scientific research into treatments for a complex, rare disease involving 250+ affected genes on the short arm of the 8 th chromosome (8p). Rearrangements of these genes causes significant abnormalities to the entire neurological system, thus all organs and functions of the body– with variance in cognitive functions, gross motor skills, social development and other challenges during infancy, and throughout life;
  • Empower a unified community of 8p patients and their families so they can have meaningful lives today; and
  • Accelerate future treatments, not only for 8p, but potentially for other chromosome-wide diseases as well.